TECX Stock Analysis: Tectonic Therapeutic | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 528m USD | 12M Return: 60.9% | US8789721086 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.72M
Warnings
Tailwinds
Seasonality 8.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Tectonic Therapeutic, Inc. (NASDAQ: TECX) is a clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that target G protein-coupled receptors (GPCRs), one of the largest and most validated classes of drug targets in human disease. The company leverages its proprietary GEODe technology platform to engineer biologic medicines aimed at GPCRs that have historically been difficult to address with traditional small-molecule approaches. Its lead candidate, TX45, is an Fc-relaxin fusion molecule designed to activate the RXFP1 receptor for the treatment of cardiovascular disease associated with heart failure with preserved ejection fraction (HFpEF).
In addition to TX45, Tectonic is advancing a pipeline that includes TX2100 for hereditary hemorrhagic telangiectasia (HHT), a bispecific GPCR modulator for fibrosis, and other early-stage GPCR-targeted programs. Like many development-stage biotechnology companies, Tectonic is headquartered in Watertown, Massachusetts, a region anchored by the Greater Boston life sciences cluster, and operates as a small-cap company within the broader healthcare sector. Its business model is centered on translating its platform and pipeline candidates into partnerships, licensing agreements, or commercialized products, with revenue largely dependent on future clinical and regulatory milestones rather than current product sales.
- TX45 Phase 2 pulmonary hypertension data readout approaches
- Cash runway extension through key clinical milestones
- Pipeline expansion advances with TX2100 HHT program
- Partnership deals could validate GEODe GPCR platform
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA -8.74 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -72.1m > Net Income -85.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.0m) vs 12m ago 1.52% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -2.14k > 6 (EBIT TTM -85.4m / Interest Expense TTM 40.0k) |
| A: 0.93 (Total Current Assets 231.1m - Total Current Liabilities 10.4m) / Total Assets 237.0m |
| B: -1.14 (Retained Earnings -270.3m / Total Assets 237.0m) |
| C: -0.32 (EBIT TTM -85.4m / Avg Total Assets 266.2m) |
| D: 16.97 (Book Value of Equity 223.8m / Total Liabilities 13.2m) |
| Altman-Z'' = 18.06 = AAA |
As of September 25, 2026, the stock is trading at USD 24.12 with a total of 214,408 shares traded. Over the past week, the price has changed by -11.36%, over one month by -33.86%, over three months by -21.48% and over the past year by +60.91%.
Current recommended Stop Loss: 21.90 (which is 9.2% or 1.2 ATR below the current price).
Tectonic Therapeutic has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy TECX.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 76.6 | 217.7% |
P/B = 2.3563
Revenue TTM = 0.0 USD
EBIT TTM = -85.4m USD
EBITDA TTM = -83.8m USD
Long Term Debt = 2.82m USD (estimated: total debt 4.40m - short term 1.58m)
Short Term Debt = 1.58m USD (from shortTermDebt, last quarter)
Debt = 4.40m USD (from shortLongTermDebtTotal, last quarter) (leases 4.40m already included)
Net Debt = -222.7m USD (calculated: Debt 4.40m - CCE 227.1m)
Enterprise Value = 305.2m USD (527.8m + Debt 4.40m - CCE 227.1m)
Interest Coverage Ratio = -2.14k (Ebit TTM -85.4m / Interest Expense TTM 40.0k)
EV/FCF = -4.21x (Enterprise Value 305.2m / FCF TTM -72.4m)
FCF Yield = -23.74% (FCF TTM -72.4m / Enterprise Value 305.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.29 (Enterprise Value 305.2m / Total Assets 237.0m)
Interest Expense / Debt = 0.91% (Interest Expense 40.0k / Debt 4.40m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -67.5m (EBIT -85.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.29 (Total Current Assets 231.1m / Total Current Liabilities 10.4m)
Debt / Equity = 0.02 (Debt 4.40m / totalStockholderEquity, last quarter 223.8m)
Debt / EBITDA = 2.66 (negative EBITDA) (Net Debt -222.7m / EBITDA -83.8m)
Debt / FCF = 3.07 (negative FCF - burning cash) (Net Debt -222.7m / FCF TTM -72.4m)
Total Stockholder Equity = 243.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.23% (Net Income -85.8m / Total Assets 237.0m)
RoE = -35.26% (Net Income TTM -85.8m / Total Stockholder Equity 243.3m)
RoCE = -34.71% (EBIT -85.4m / Capital Employed (Equity 243.3m + L.T.Debt 2.82m))
RoIC = -29.56% (negative operating profit) (NOPAT -67.5m / Invested Capital 228.2m)
WACC = 11.74% (E(527.8m)/V(532.2m) * Re(11.83%) + D(4.40m)/V(532.2m) * Rd(0.91%) * (1-Tc(0.21)))
Discount Rate = 11.83% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.93 | Cagr: 105.9%
[DCF] Fair Price = unknown (Cash Flow -72.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-1.33 | Chg30d=+2.83% | Revisions=-25% | Analysts=8
EPS current Year (2026-12-31): EPS=-5.09 | Chg30d=-0.03% | Revisions=+25% | GrowthEPS=-25.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.38 | Chg30d=+0.50% | Revisions=-25% | GrowthEPS=-5.7% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -17% (up=1, down=2)